73 results on '"Moliterno, David"'
Search Results
2. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy
3. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups
4. Outcomes in African Americans and whites after percutaneous coronary intervention
5. Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
6. Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis
7. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry
8. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans
9. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
10. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial
11. Sudden Cardiac Death After Non–ST-Segment Elevation Acute Coronary Syndrome
12. Effects of glycoprotein IIb/IIIa blockers
13. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients
14. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
15. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial
16. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
17. Platelet protease-activated receptor antagonism in cardiovascular medicine
18. Contemporary use of glycoprotein IIb/IIIa inhibitors
19. Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting
20. Is There an Association Between External Cardioversions and Long-Term Mortality and Morbidity
21. Upstream Use of Small-Molecule Glycoprotein IIbIIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
22. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting
23. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
24. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents
25. Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention
26. Renal function, concomitant medication use and outcomes following acute coronary syndromes.
27. Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices
28. Assessing the Effect of Publication of Clinical Guidelines on the Management of Unstable Angina and NonST Elevation Myocardial Infarction in The TIMI III 19901993 and the GUARANTEE 19951996 Registries
29. Glycoprotein IIb/IIIa Antagonism and Fibrinolytic Therapy for Acute Myocardial Infarction
30. Defining the role of abciximab for acute coronary syndromes Lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET
31. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb11Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network (PARAGON-A); Global Use of Strategies To Open occluded arteries in acute coronary syndromes (GUSTO-IIb).
32. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
33. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction
34. Platelet glycoprotein IIb/IIIa receptor antagonists
35. Bedside activated partial thromboplastin time monitoring: Just a matter of time?
36. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions
37. Subacute stent thrombosis: Evolving issues and current concepts
38. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin
39. Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE registry
40. Hemodynamic effects of intranasal cocaine in humans
41. Case Report: Coronary Vasospasm—Relation to the Hyperthyroid State
42. Conjunctive Use of Platelet Glycoprotein IIb/IIIa Antagonists and Thrombolytic Therapy for Acute Myocardial Infarction
43. Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction fn1fn1The GUSTO-I study was supported by a combined grant from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genetech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France.
44. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
45. Effectiveness of PCI for non-acute coronary artery disease
46. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention
47. Diabetes and percutaneous coronary intervention: The sweet smell of success?
48. Another step toward resolving the contrast controversy
49. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention
50. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.